Henry Schein, Inc. (NASDAQ:HSIC) – Equities research analysts at Barrington Research upped their Q3 2017 earnings per share (EPS) estimates for Henry Schein in a note issued to investors on Wednesday. Barrington Research analyst M. Petusky now anticipates that the company will earn $1.79 per share for the quarter, up from their previous estimate of $1.78. Barrington Research currently has a “Outperform” rating and a $198.00 price objective on the stock. Barrington Research also issued estimates for Henry Schein’s Q1 2018 earnings at $1.87 EPS, Q2 2018 earnings at $1.94 EPS, Q4 2018 earnings at $2.22 EPS, FY2018 earnings at $8.00 EPS and FY2019 earnings at $8.80 EPS.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The business had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the firm earned $1.64 earnings per share. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “Barrington Research Analysts Boost Earnings Estimates for Henry Schein, Inc. (HSIC)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/11/barrington-research-analysts-boost-earnings-estimates-for-henry-schein-inc-hsic.html.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a report on Thursday, July 6th. Piper Jaffray Companies started coverage on shares of Henry Schein in a report on Monday, June 12th. They set a “neutral” rating and a $200.00 price objective on the stock. Finally, Credit Suisse Group restated a “hold” rating and set a $160.00 price objective on shares of Henry Schein in a report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company’s stock. Henry Schein currently has a consensus rating of “Hold” and a consensus price target of $185.56.

Henry Schein (NASDAQ HSIC) opened at 167.32 on Friday. The stock has a 50 day moving average of $181.94 and a 200-day moving average of $175.01. Henry Schein has a 12 month low of $146.23 and a 12 month high of $186.99. The company has a market cap of $13.25 billion, a P/E ratio of 24.45 and a beta of 1.09.

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Henry Schein by 2,999.6% in the first quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock valued at $951,028,000 after buying an additional 5,414,761 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Henry Schein during the first quarter valued at approximately $50,281,000. Marshall Wace North America L.P. purchased a new stake in shares of Henry Schein during the first quarter valued at approximately $50,281,000. PGGM Investments purchased a new stake in shares of Henry Schein during the second quarter valued at approximately $32,623,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Henry Schein by 12.4% in the first quarter. JPMorgan Chase & Co. now owns 1,515,861 shares of the company’s stock valued at $257,650,000 after buying an additional 167,213 shares in the last quarter. Institutional investors own 90.87% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.